Global Angelman Syndrome Treatment Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado de tratamentos para a síndrome de Angelman

A incidência das síndromes de Angelman pode variar entre as diferentes populações e faixas etárias. No entanto, o aumento das iniciativas governamentais no desenvolvimento de opções de tratamento para a síndrome de angelman impulsiona o mercado global de tratamento da síndrome de angelman. Além disso, o aumento dos gastos em saúde e I&D também impulsiona o crescimento do mercado.  

A Data Bridge Market Research analisa que o mercado de tratamento da síndrome de angelman, que foi de 143,77 milhões de dólares em 2022, subiria para 220,64 milhões de dólares até 2030, e deverá passar por um CAGR de 5,5% durante o período de previsão. Este indica o valor de mercado. A “fisioterapia” domina o segmento de tratamento do mercado de tratamento da síndrome de Angelman devido à crescente procura de melhores métodos cirúrgicos para o tratamento. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado de tratamentos da síndrome de Angelman

Definição de mercado

A síndrome de Angelman é uma doença genética muito rara que afeta o sistema nervoso. Esta síndrome é causada por uma perda de função do gene UBE3A no 15º cromossoma materno. As pessoas que sofrem do transtorno do homem-anjo têm personalidades excitáveis ​​e riem e sorriem frequentemente. Os principais sintomas da síndrome de Angelman são a falta de fala, problemas de equilíbrio e convulsões. Por vezes, podem ocorrer movimentos espasmódicos.

Dinâmica global do mercado de tratamentos para a síndrome de Angelman

Motoristas

• Prevalência crescente de perturbações da fala

Espera-se que a crescente prevalência de distúrbios da fala, como a gaguez, a apraxia e outros entre crianças e adultos, alimente o mercado global de tratamentos da síndrome de Angelman. Além disso, espera-se também que a crescente prevalência de doenças crónicas, como lesões cerebrais, tumores, doença de Parkinson , autismo, paralisia cerebral e acidente vascular cerebral, impulsione o mercado global de tratamentos da síndrome de Angelman. As perturbações expressivas, as perturbações da voz, as perturbações da articulação, as perturbações da fluência e as perturbações da linguagem, como as perturbações recetivas e as perturbações da comunicação cognitiva, são todos casos de perturbações da fala. O surgimento destes distúrbios está a impulsionar o mercado global de tratamentos para a síndrome de Angelman.

• Aumentar o investimento em infraestruturas de saúde

Outro fator significativo que influencia a taxa de crescimento do mercado de tratamentos da síndrome de angelman é o aumento dos gastos com a saúde que ajuda a melhorar as suas infraestruturas. Além disso, várias organizações governamentais pretendem melhorar a infra-estrutura de saúde aumentando o financiamento e isto influenciará ainda mais a dinâmica do mercado.

Oportunidades

• Proficiências em investigação e desenvolvimento

O aumento dos gastos com proficiências em investigação e desenvolvimento, especialmente nas economias desenvolvidas e em desenvolvimento, relativos aos tratamentos da síndrome de Angelman, criará ainda mais oportunidades lucrativas de crescimento do mercado. As proficiências em investigação e desenvolvimento conduzidas para fornecer os melhores medicamentos para conter a Síndrome de Angelman estão também a reforçar a taxa de crescimento do mercado.

• Increase in the number of research and development activities       

The increase in the number of research and development activities is estimated to provide various beneficial opportunities for the neurological disorder drugs market’s growth. New therapeutic techniques for the treatment of angelman syndrome are being adopted by companies in the neurological disorder pharmaceuticals market. This leads to high number of research activities to better understand the disease's genetic risk factors in order to find better drugs.

Restraints/Challenges

• Hight costs associated with the research and development activities

The high cost associated with the research and development activities will obstruct the growth rate of market

This angelman syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Angelman Syndrome Treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Development

• In September 2021, Sumitomo Dainippon Pharma and Otsuka announced a collaboration as well as license agreement for four psychiatry and neurology compounds namely ulotaront (SEP-363856), SEP-4199, SEP-378614, and SEP-380135. Under the terms of the partnership, Sunovion and Otsuka will split the costs and revenues of clinical trials, regulatory applications, and commercialization in each of these nations and areas. Additional ulotaront indications, and also SEP-378614 and SEP-380135 indications, will be identified after future Sumitomo Dainippon Pharma Group and Otsuka consultations.

Global Angelman Syndrome Treatment Market Scope

The angelman syndrome treatment market is segmented on the basis of treatment, service provider, diagnostic test and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Physical Therapy
• Communication Therapy
• Behavior Therapy
• Others

 Service Provider

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Diagnostic Test

• DNA methylation test
• Chromosomal Microarray (CMA)
• Gene mutation Tests
• Other

End Users

• Clinic
• Hospital
• Others

Global Angelman Syndrome Treatment Market Regional Analysis/Insights

The global angelman syndrome treatment market is analysed and market size insights and trends are provided by country, treatment, service provider, diagnostic test and end-users as referenced above.

The countries covered in the angelman syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the angelman syndrome treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having Angelman Syndromes such as moles, warts and skin tags.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for skin care, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The angelman syndrome treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Angelman Syndrome treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Angelman Syndrome market.

Competitive Landscape and Angelman Syndrome Treatment  Market Share Analysis

The angelman syndrome treatment market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the angelman syndrome treatment market.

Some of the major players operating in the angelman syndrome treatment market are:

• Smart Speech Therapy (U.S.)

• SPEECH THERAPY SOLUTIONS, INC. (U.S.)

• Talk Speech and Language Therapy Ltd. (U.K.)

• Glenda Browne Speech Pathology (Australia)

• Benchmark Therapies, Inc (U.S.)

• speech plus (U.S.)

• Integrated Treatment Services (U.S.)

• Speechworks Therapy Services (U.S.)

• Acapela Group (Belgium)

• Advanced Voice Recognition Systems, Inc. (U.S.)

• Open Text Corporation (Canada)

• Cleveland Clinic (U.S.)

• Therapy Solutions Inc (U.S.)

• Merck KGaA (Germany)

• Eisai Co., Ltd. (Japan)

• AstraZeneca (U.K.)

• Sanofi (France)

• Novartis AG (Switzerland)

• Abbott (U.S.)

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Teva Pharmaceutical Industries Ltd. (Ireland)

• Pfizer Inc. (U.S.)

• GlaxoSmithKline plc (U.K.)

SKU-60302